NeoDynamics enters a scientific partnership to evaluate its technology platform in osteoarthritis
NeoDynamics AB (publ), (Spotlight Stockholm: NEOD), today announced that the Company joins in a research collaboration with the William Hunter Revisited research consortium to evaluate NeoNavia pulse biopsy system for joint tissue sampling in a new potential indication, osteoarthritis.
The William Hunter Revisited research consortium consists of six universities and academic hospitals and is collaborating with industry to identify biomarkers and test new diagnostic devices for monitoring disease progression and repair as well as developing regenerative therapies for osteoarthritis.
“We look forward to collaborating with NeoDynamics and leveraging their expertise and technology to improve biopsy technique and tissue sampling in patients with osteoarthritis”, says Dr. Pieter Emans, Orthopedic Surgeon at Maastricht UMC.
“The collaboration with the consortium is a great opportunity for NeoDynamics, it gives us access to a network of leading clinicians and researchers in the field of osteoarthritis. Naturally we are interested to evaluate our technology platform beyond the breast cancer area”, says Kai-Uwe Schässburger, Ph.D. Director Clinical Development & Medical Affairs of NeoDynamics. “This will further validate our pulse biopsy system NeoNavia and explore the potential use in Osteoarthritis”.
Osteoarthritis is the most common form of arthritis, affecting more than 100 million patients around the world. It occurs when the protective cartilage that cushions the end of the bones gradually deteriorates and is the 4th leading cause of mobility-associated disability. Osteoarthritis is a degenerative disease that worsens over time often resulting in chronic pain. Societal costs are immense and reaching 15 Billion per year in the Netherlands alone. There is a significant need to developing innovative tools for tissue sampling, and analysis of disease progression to optimize individual treatment options.
The information was submitted for publication through the agency of the contact person set out below, at 08:55 CET on November 12, 2020
For additional information please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ). Phone +46 708 444 966 e-mail: firstname.lastname@example.org
Jörgen Vrenning, CFO/IR NeoDynamics AB (publ). Phone +46 708 519 648 e-mail: email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia. The precision biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.
NeoNavia is the brand name for the entire biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
About the pulse technology
The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type. The pneumatic driver that generates micro-pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.
Information about Attana’s presentation at Stora Aktiedagen streamed live on December 2[nd] 09:00-09:30
Attana was founded in 2002 with the vision ofin vitrocharacterization of molecular interactions mimickingin vivoconditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (A...
Information om Attanas presentation på Stora Aktiedagen som streamas live 2 december kl. 09.00–09.30
Attana AB grundades 2002 med idén att effektivisera forskning och utveckling av nya läkemedel genom biologisk interaktionskarakterisering i realtid. Baserat på sina patenterade teknologier säljer bolaget uppdragsforskning och egenproducerade analysinstrument samt ett in vitro diagnostiskt (IVD) verk...
Positiva diskussioner på SpectraCures Investigator Meeting
SpectraCure har arrangerat ett Investigator Meeting där statistik och resultat från genomförda behandlingar i bolagets kliniska studie diskuterats.Mötesdiskussionerna ligger även till grund för den kommande ansökan om accelerated approval. Under mötet deltog läkare och representanter för de kl...
FÖRSTA ALGORITMEN I STROKEFINDER VISAR BRA PRESTANDA
Utvecklingsarbetet och den kliniska insamlingen av data har nu resulterat i att den första algoritmen i MD100 har nått en prestanda som bolaget och sjukvården bedömer är tillräckligt hög för att lansera första generationen MD100 på marknaden. Det här betyder att Medfield nu påbörjar arbetet med att...